•Safety is an unaddressed issue for some current
patients
•
•Insurer Balens (Summer 2010) – will wait for individual cases, no desire to issue guidance
•
•Practitioner liability means doing nothing is not an
option
•
•EFSA changes to SULs/GLs will make little
difference
•
•Advice from companies is unlikely to be adequate
•
•BANT plays a key role in maintaining standards
CPD Criteria - companies should address safety issues: dose >SUL/GL, duration of use, major contraindications and
warnings
Formal Guidance on supplement safety would be helpful